InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-7.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Nussbaum Ran, Director. Officer active across 3 companies, notably Eloxx Pharmaceuticals, Inc.. Cumulatively, 12 filings have been recorded. Breakdown: 2 buys · 0 sell. Total volume traded: €2.9m. History available since 13 May 2021. The latest transaction was filed on 21 October 2022 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations12 total
47,999 shares@ US$5.9446.2% of flowOrdinary SharesSEC:0001437749-23-004868:0
1,030 shares@ US$5.000.8% of flowOrdinary SharesSEC:0001437749-23-004870:0
2,211 shares@ US$5.001.7% of flowOrdinary SharesSEC:0001437749-23-004866:0
3,539 shares@ US$0.0001100.0% of flowCommon StockSEC:0001209191-22-059052:0
47,999 shares@ US$5.9446.2% of flowOrdinary SharesSEC:0001437749-22-024711:0
1,030 shares@ US$5.000.8% of flowOrdinary SharesSEC:0001437749-22-021338:0
1,030 shares@ US$5.000.0003% mcap15.9% of flowOrdinary SharesSEC:0001209191-21-039137:0
1,030 shares@ US$5.000.7% of flowOrdinary SharesSEC:0001209191-21-039137
2,211 shares@ US$5.000.0007% mcap34.1% of flowOrdinary SharesSEC:0001209191-21-039132:0
2,211 shares@ US$5.001.5% of flowOrdinary SharesSEC:0001209191-21-039132
1,280,624 shares@ US$1.3550.0% of flowCommon StockSEC:0001104659-21-067335:0
Ideal exit: 7 Feb 2022 (T+270)
1,280,624 shares@ US$1.3550.0% of flowCommon StockSEC:0001104659-21-067335
Ideal exit: 7 Feb 2022 (T+270)
12 of 12 declarations
About Nussbaum Ran
Ran Nussbaum is a Board Member at Eloxx Pharmaceuticals, Inc. and UroGen Pharma Ltd. He is responsible for overseeing the operations and strategy of these companies. His experience in the pharmaceutical sector allows him to make significant contributions to strategic discussions. As a board member, he ensures that decisions made align with the growth and innovation objectives of the companies.
